Terms: = Breast cancer AND PRCC, Q92733, TPRC, RCCP1, MGC4723, MGC17178, ENSG00000143294, 5546
15 results:
1. The clinicopathologic and molecular features, and treatment outcome of fumarate hydratase-deficient renal cell carcinoma: a retrospective comparison with type 2 papillary renal cell carcinoma.
Bai J; Li X; Wen Y; Lu Q; Chen R; Liu R; Shangguan T; Ye Y; Lin J; Cai W; Kang D; Chen J
Aging (Albany NY); 2024 Feb; 16(4):3631-3646. PubMed ID: 38376408
[TBL] [Abstract] [Full Text] [Related]
2. Identification of prognostic and therapeutic biomarkers in type 2 papillary renal cell carcinoma.
Wang Y; Tian X; Zhu SX; Xu WH; Anwaier A; Su JQ; Gan HL; Qu YY; Zhao JY; Zhang HL; Ye DW
World J Surg Oncol; 2023 Mar; 21(1):98. PubMed ID: 36927438
[TBL] [Abstract] [Full Text] [Related]
3. The prognostic impact of Claudin 6 in papillary renal cell carcinoma.
Mikuteit M; Zschäbitz S; Stöhr C; Herrmann E; Polifka I; Agaimy A; Trojan L; Ströbel P; Becker F; Wülfing C; Barth P; Stöckle M; Staehler M; Stief C; Haferkamp A; Hohenfellner M; Macher-Göppinger S; Wullich B; Noldus J; Brenner W; Roos FC; Walter B; Otto W; Burger M; Schrader AJ; Hartmann A; Steffens S; Erlmeier F
Pathol Res Pract; 2022 Mar; 231():153802. PubMed ID: 35180650
[TBL] [Abstract] [Full Text] [Related]
4. The first competing risk survival nomogram in patients with papillary renal cell carcinoma.
Su X; Hou NN; Yang LJ; Li PX; Yang XJ; Hou GD; Gao XL; Ma SJ; Guo F; Zhang R; Zhang WH; Qin WJ; Wang FL
Sci Rep; 2021 Jun; 11(1):11835. PubMed ID: 34088935
[TBL] [Abstract] [Full Text] [Related]
5. Zolpidem reduces pain intensity postoperatively: a systematic review and meta-analysis of the effect of hypnotic medicines on post-operative pain intensity.
O'Hagan ET; Hübscher M; Miller CB; Gordon CJ; Gustin S; Briggs N; McAuley JH
Syst Rev; 2020 Sep; 9(1):206. PubMed ID: 32883342
[TBL] [Abstract] [Full Text] [Related]
6. Identification of novel prognostic alternative splicing signature in papillary renal cell carcinoma.
Duan Y; Zhang D
J Cell Biochem; 2020 Jan; 121(1):672-689. PubMed ID: 31407370
[TBL] [Abstract] [Full Text] [Related]
7. A five-gene signature predicts overall survival of patients with papillary renal cell carcinoma.
Gao Z; Zhang D; Duan Y; Yan L; Fan Y; Fang Z; Liu Z
PLoS One; 2019; 14(3):e0211491. PubMed ID: 30822312
[TBL] [Abstract] [Full Text] [Related]
8. The knockdown of the mediator complex subunit MED30 suppresses the proliferation and migration of renal cell carcinoma cells.
Syring I; Weiten R; Müller T; Schmidt D; Steiner S; Müller SC; Kristiansen G; Ellinger J
Ann Diagn Pathol; 2018 Jun; 34():18-26. PubMed ID: 29661722
[TBL] [Abstract] [Full Text] [Related]
9. Onconeuronal antigen Cdr2 correlates with HIF prolyl-4-hydroxylase PHD1 and worse prognosis in renal cell carcinoma.
Kaufmann MR; Schraml P; Hermanns T; Wenger RH; Camenisch G
Exp Mol Pathol; 2013 Jun; 94(3):453-7. PubMed ID: 23531419
[TBL] [Abstract] [Full Text] [Related]
10. Expression of parafibromin in major renal cell tumors.
Cui C; Lal P; Master S; Ma Y; Baradet T; Bing Z
Eur J Histochem; 2012 Oct; 56(4):e39. PubMed ID: 23361235
[TBL] [Abstract] [Full Text] [Related]
11. Expression of S100A4 in renal epithelial neoplasms.
Wang LJ; Matoso A; Sciandra KT; Yakirevich E; Sabo E; Zhang Y; Meitner PA; Tavares R; Noble L; Pareek G; DeLellis RA; Resnick MB
Appl Immunohistochem Mol Morphol; 2012 Jan; 20(1):71-6. PubMed ID: 21691200
[TBL] [Abstract] [Full Text] [Related]
12. Onconeuronal cerebellar degeneration-related antigen, Cdr2, is strongly expressed in papillary renal cell carcinoma and leads to attenuated hypoxic response.
Balamurugan K; Luu VD; Kaufmann MR; Hofmann VS; Boysen G; Barth S; Bordoli MR; Stiehl DP; Moch H; Schraml P; Wenger RH; Camenisch G
Oncogene; 2009 Sep; 28(37):3274-85. PubMed ID: 19581925
[TBL] [Abstract] [Full Text] [Related]
13. Molecular cloning and characterization of FBXO47, a novel gene containing an F-box domain, located in the 17q12 band deleted in papillary renal cell carcinoma.
Simon-Kayser B; Scoul C; Renaudin K; Jezequel P; Bouchot O; Rigaud J; Bezieau S
Genes Chromosomes Cancer; 2005 May; 43(1):83-94. PubMed ID: 15723337
[TBL] [Abstract] [Full Text] [Related]
14. [Heredity in renal and prostatic neoplasia].
Prayer Galetti T; D'Arrigo L; De Zorzi L; Patarnello T
Arch Ital Urol Androl; 1997 Sep; 69(4):241-6. PubMed ID: 9417296
[TBL] [Abstract] [Full Text] [Related]
15. HIV/AIDS mortality in Canada: evidence of gender, regional and local area differentials.
Hogg RS; Heath KV; Strathdee SA; Montaner JS; O'Shaughnessy MV; Schechter MT
AIDS; 1996 Jul; 10(8):889-94. PubMed ID: 8828746
[TBL] [Abstract] [Full Text] [Related]
